Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects

Abstract

Background & aims: Nonalcoholic fatty liver disease is associated with insulin resistance and diabetes. The purpose of this study was to determine the relationship between intrahepatic triglyceride (IHTG) content and insulin action in liver (suppression of glucose production), skeletal muscle (stimulation of glucose uptake), and adipose tissue (suppression of lipolysis) in nondiabetic obese subjects.

Methods: A euglycemic-hyperinsulinemic clamp procedure and stable isotopically labeled tracer infusions were used to assess insulin action, and magnetic resonance spectroscopy was used to determine IHTG content, in 42 nondiabetic obese subjects (body mass index, 36 +/- 4 kg/m(2)) who had a wide range of IHTG content (1%-46%).

Results: Hepatic insulin sensitivity, assessed as a function of glucose production rate and plasma insulin concentration, was inversely correlated with IHTG content (r = -0.599; P < .001). The ability of insulin to suppress fatty acid release from adipose tissue and to stimulate glucose uptake by skeletal muscle were also inversely correlated with IHTG content (adipose tissue: r = -0.590, P < .001; skeletal muscle: r = -0.656, P < .001). Multivariate linear regression analyses found that IHTG content was the best predictor of insulin action in liver, skeletal muscle, and adipose tissue, independent of body mass index and percent body fat, and accounted for 34%, 42%, and 44% of the variability in these tissues, respectively (P < .001 for each model).

Conclusions: These results show that progressive increases in IHTG content are associated with progressive impairment of insulin action in liver, skeletal muscle, and adipose tissue in nondiabetic obese subjects. Therefore, nonalcoholic fatty liver disease should be considered part of a multiorgan system derangement in insulin sensitivity.

Figure 1

Relationship between intra-abdominal adipose tissue volume and intrahepatic triglyceride content.

Figure 2

Relationships between: 1) hepatic insulin sensitivity and intrahepatic triglyceride content (Top Panel); 2) insulin-mediated suppression of palmitate Ra during stage 1 of the euglycemic-hyperinsulinemic clamp procedure and intrahepatic triglyceride content (Middle Panel); and 3) insulin-mediated stimulation of glucose uptake (glucose Rd) during stage 2 of the euglycemic-hyperinsulinemic clamp procedure and intrahepatic triglyceride content (Bottom Panel).

Figure 2

Relationships between: 1) hepatic insulin sensitivity and intrahepatic triglyceride content (Top Panel); 2) insulin-mediated suppression of palmitate Ra during stage 1 of the euglycemic-hyperinsulinemic clamp procedure and intrahepatic triglyceride content (Middle Panel); and 3) insulin-mediated stimulation of glucose uptake (glucose Rd) during stage 2 of the euglycemic-hyperinsulinemic clamp procedure and intrahepatic triglyceride content (Bottom Panel).

Figure 2

Relationships between: 1) hepatic insulin sensitivity and intrahepatic triglyceride content (Top Panel); 2) insulin-mediated suppression of palmitate Ra during stage 1 of the euglycemic-hyperinsulinemic clamp procedure and intrahepatic triglyceride content (Middle Panel); and 3) insulin-mediated stimulation of glucose uptake (glucose Rd) during stage 2 of the euglycemic-hyperinsulinemic clamp procedure and intrahepatic triglyceride content (Bottom Panel).